| Question 1: The difference between 4D dose and dynamic 4D dose is: |
| Reference: | AAPM Task Group 290 report |
| Choice A: | 4D dose includes delivery timing information but dynamic 4D dose does not |
| Choice B: | Dynamic 4D dose includes delivery timing information but 4D dose does not |
| Choice C: | 4D dose is based on 4DCT and dynamic 4D dose is not |
| Choice D: | Dynamic 4D dose is based on 4DCT and 4D dose is not |
| Choice E: | There is no difference |
| Question 2: 4DCT is NOT typically used for: |
| Reference: | AAPM Task Group 290 report |
| Choice A: | Motion assessment |
| Choice B: | Tumor contouring |
| Choice C: | Treatment Planning |
| Choice D: | Treatment Delivery |
| Question 3: Which of the following techniques is not routinely used for patient motion monitoring during treatment delivery: |
| Reference: | AAPM Task Group 290 report |
| Choice A: | Fluoroscopy X-ray |
| Choice B: | Optical surface imaging |
| Choice C: | Ultrasound imaging |
| Choice D: | None of above |
| Question 4: Large proton pencil beam scanning spots can be employed to: |
| Reference: | Proton pencil beam scanning for mediastinal lymphoma: the impact of interplay between target motion and beam scanning: C Zeng, J, P Plastaras, Z A Tochner, B M White, C E Hill-Kayser, S M Hahn and S Both
Phys. Med. Biol. 60 (2015) 3013–3029 |
| Choice A: | Mitigate the interplay effect |
| Choice B: | Improve target dose conformity |
| Choice C: | Decrease target dose robustness |
| Choice D: | Decrease dose to organs at risk |
| Question 5: The respiratory correlated 4DCT can be used: |
| Reference: | Evaluation of interplay and organ motion effects by means of 4D dose reconstruction and accumulation: Arturs Meijers Antje-Christin Knopf Anne P.G. Crijns Jan F. Ubbels Anne G.H. Niezink Johannes A. Langendijk Robin Wijsman, Stefan Both; Radiotherapy and Oncology 150 (2020) 268–274 |
| Choice A: | Online for target dose reconstruction and accumulation |
| Choice B: | Offline for target dose reconstruction and accumulation |
| Choice C: | Offline for intrinsic cardiac motion evaluation |
| Choice D: | Online for organs at risk dose reconstruction and accumulation |
| Question 6: The largest contributor to target dose degradation for 3D robustly optimized thorax IMPT treatments is the: |
| Reference: | Evaluation of interplay and organ motion effects by means of 4D dose reconstruction and accumulation: Arturs Meijers Antje-Christin Knopf Anne P.G. Crijns Jan F. Ubbels Anne G.H. Niezink Johannes A. Langendijk Robin Wijsman, Stefan Both; Radiotherapy and Oncology 150 (2020) 268–274 |
| Choice A: | Interplay effect |
| Choice B: | Anatomical changes |
| Choice C: | Large number of treatment fractions |
| Choice D: | Inaccuracies in HUs |
